Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,152
  • Shares Outstanding, K 13,401
  • Annual Sales, $ 33,880 K
  • Annual Income, $ -26,940 K
  • 60-Month Beta N/A
  • Price/Sales 0.89
  • Price/Cash Flow N/A
  • Price/Book 1.23
Trade CASI with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -169.12%)
  • Historical Volatility 90.87%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 363.75% on 09/26/23
  • IV Low 0.00% on 04/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 39
  • Open Int (30-Day) 143

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +18.54%
on 04/17/24
3.72 -34.68%
on 03/28/24
-0.63 (-20.59%)
since 03/22/24
3-Month
2.05 +18.54%
on 04/17/24
8.19 -70.33%
on 01/26/24
-2.58 (-51.50%)
since 01/22/24
52-Week
1.85 +31.35%
on 06/16/23
8.48 -71.34%
on 12/12/23
-0.58 (-19.27%)
since 04/21/23

Most Recent Stories

More News
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.43 (+8.00%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.43 (+8.00%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 2.43 (+8.00%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.43 (+8.00%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 2.43 (+8.00%)
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ACRX : 0.8600 (+7.50%)
CASI : 2.43 (+8.00%)
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.43 (+8.00%)
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MDWD : 15.76 (-0.06%)
CASI : 2.43 (+8.00%)
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

FHTX : 5.05 (-4.72%)
CASI : 2.43 (+8.00%)
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.43 (+8.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 2.75
2nd Resistance Point 2.62
1st Resistance Point 2.53
Last Price 2.43
1st Support Level 2.31
2nd Support Level 2.18
3rd Support Level 2.09

See More

52-Week High 8.48
Fibonacci 61.8% 5.95
Fibonacci 50% 5.16
Fibonacci 38.2% 4.38
Last Price 2.43
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar